Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of a sequential regimen of induction chemotherapy with panitumumab and paclitaxel followed by radiotherapy plus panitumumab in patients with head and neck cancer, locally advanced non-candidates for treatment with platinum. (Ensayo de fase II de un régimen secuencial de quimioterapia de inducción con panitumumab y paclitaxel seguida de radioterapia más panitumumab en pacientes con cáncer de cabeza y cuello localmente avanzado que no son candidatos al tratamiento con derivados de platino)

Next Previous
Trial Profile

Phase II trial of a sequential regimen of induction chemotherapy with panitumumab and paclitaxel followed by radiotherapy plus panitumumab in patients with head and neck cancer, locally advanced non-candidates for treatment with platinum. (Ensayo de fase II de un régimen secuencial de quimioterapia de inducción con panitumumab y paclitaxel seguida de radioterapia más panitumumab en pacientes con cáncer de cabeza y cuello localmente avanzado que no son candidatos al tratamiento con derivados de platino)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Panitumumab (Primary) ; Paclitaxel
  • Indications Adenosquamous carcinoma; Carcinoma; Head and neck cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms PANTERA

    • Most Recent Events

    • 17 Sep 2019 According to an Amgen media release, final results from this trial will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, Sept. 27-Oct. 1, 2019.
    • 04 Feb 2013 Planned number of patients changed to 61.
    • 04 Feb 2013 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top